Normal BMI Does Not Exclude Metabolic Liver Disease

Metabolic dysfunction–associated steatotic liver disease MASLD is still too often filtered through body size first and biology second. The condition is usually linked to excess adiposity, insulin resistance, type 2 diabetes, and broader cardiometabolic injury, so clinicians naturally gravitate toward body mass index as a quick risk screen. But that shortcut breaks down in a clinically important subgroup: patients with lean MASLD, whose liver disease emerges despite a normal-range BMI.

A normal weight therefore does not guarantee a normal metabolic liver profile. The consequence is practical and immediate at the bedside, because patients who appear low-risk by habit or habitus can still carry hepatic steatosis and the metabolic dysfunction that drives it.

Why BMI Misses the Biology

BMI is a crude measure. It tells us little about visceral fat distribution, hepatic fat handling, insulin sensitivity, or the inflammatory milieu that links metabolic dysfunction to liver injury. Two patients with the same BMI can have very different metabolic burdens: one may have relatively favorable adipose partitioning, while another stores disproportionate lipid in the liver and abdomen, where it is more likely to fuel hepatocellular stress.

That distinction matters because MASLD is not simply a disorder of excess body weight. It is a disorder of disordered metabolism, and adiposity is only one visible expression of that biology. When BMI is treated as a proxy for risk, the model works reasonably well for many patients but fails in those whose metabolic dysfunction is not mirrored by overt obesity. Lean MASLD is the clearest example of that failure.

The abstract makes the central clinical problem plain: a visible proxy can become a misleading one when it is allowed to stand in for pathophysiology. In lean patients, the absence of obvious obesity may delay suspicion, reduce the likelihood of liver-focused evaluation, and encourage false reassurance in routine care.

Lean MASLD Exposes a Screening Gap

Patients with normal BMI can still develop clinically relevant steatotic liver disease. Their presentation challenges the habit of reserving concern for people with more obvious adiposity, especially when the liver abnormality is discovered incidentally or when metabolic testing is incomplete. A BMI-centered approach may also obscure the need to look beyond weight alone for markers of insulin resistance, dyslipidemia, or other cardiometabolic abnormalities that can coexist with hepatic steatosis.

This is not a semantic issue. Risk stratification determines who gets evaluated, who is monitored, and who is told that liver disease is unlikely. Lean MASLD shows that this triage can fail when body size is treated as the principal clue. In practical terms, clinicians need to be alert to MASLD even in patients who do not fit the stereotypical metabolic phenotype.

A normal body habitus can hide substantial hepatic risk.

The Clinical Cost of Overreliance on Body Size

The abstract’s broader message is that an obesity-centered framework can distort liver risk assessment. Because excess adiposity is a major driver of the global MASLD burden, the tendency to anchor on weight is understandable. Yet the same framework can miss people whose disease arises through less visible metabolic pathways. In those cases, the liver becomes the organ where metabolic injury is already apparent even when the scale does not raise suspicion.

Pathophysiologically, this makes sense. Hepatic steatosis reflects the balance between lipid delivery, lipid synthesis, oxidation, and export. When that balance is disrupted, the liver accumulates fat and becomes vulnerable to inflammation and fibrotic progression. Normal BMI does not prevent those derangements. It simply makes them easier to overlook.

Lean MASLD also raises concern for delayed diagnosis. If clinicians equate normal body size with low risk, they may not pursue liver assessment until abnormalities become more advanced or incidentally discovered. That delay may matter because metabolic liver disease is most manageable when identified before progression to more advanced injury.

What the Lean Phenotype Changes in Practice

The immediate implication is not that BMI should be abandoned, but that it should no longer be used as a stand-alone gatekeeper for suspicion. In a patient with normal body weight, hepatic steatosis still deserves consideration when metabolic risk is present or when liver enzymes, imaging, or other clinical findings point in that direction. The phenotype of lean MASLD argues for broader clinical vigilance and a more biologically grounded assessment of metabolic health.

It also pushes clinicians to separate appearance from physiology. Body size is visible; insulin resistance, ectopic fat deposition, and cardiometabolic dysfunction are often not. Lean MASLD exists precisely because the liver can reflect hidden metabolic burden before external markers make that burden obvious.

For patient care, the message is straightforward: do not let BMI close the diagnostic conversation. Lean MASLD makes clear that weight and metabolic liver risk are related, but not interchangeable.

A Narrower but More Accurate Risk Lens

The abstract does not offer outcome data, biomarker thresholds, or a new prediction model. Its value lies in defining the clinical blind spot with unusual clarity. Lean MASLD should prompt a more careful approach to risk stratification, one that treats BMI as one variable among many rather than as a surrogate for liver health.

That recalibration has real implications for screening strategy, diagnostic suspicion, and long-term monitoring. Patients with normal BMI may still harbor the same liver-directed consequences of metabolic dysfunction seen in heavier individuals, and their disease can be missed if clinicians rely too heavily on the body habitus in front of them.

The challenge now is not recognizing that lean MASLD exists. The challenge is building clinical routines that do not require obesity before they take liver disease seriously.


Reporting by Dr. A. Nikhil Krishnan, MBBS for Medicine World Foundation, with additional data provided by JAMA (Journal of the American Medical Association).